DPP-4 inhibitor-induced breast cancer metastasis was attenuated by the CXCR4 inhibitor AMD3100, with the suppression of genes associated with EMT and a mammalian target of rapamycin (mTOR) signaling pathway in the primary tumor [38,62]. This evidence concerns the gene DPP4 and neoplasm.